Nuvation Bio’s (NUVB) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Nuvation Bio (NYSE:NUVB – Free Report) in a report published on Tuesday morning,Benzinga reports. HC Wainwright currently has a $21.00 price target on the stock.

Other research analysts have also recently issued reports about the company. Wedbush reissued an “outperform” rating and issued a $11.00 target price on shares of Nuvation Bio in a research note on Wednesday, September 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvation Bio in a report on Thursday, October 15th. Citigroup reaffirmed a “market outperform” rating on shares of Nuvation Bio in a research report on Monday, October 19th. Wall Street Zen lowered Nuvation Bio from a “hold” rating to a “sell” rating in a research report on Saturday, October 10th. Finally, B. Riley Financial reiterated a “buy” rating on shares of Nuvation Bio in a report on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $13.00.

Get Our Latest Report on NUVB

Nuvation Bio Price Performance

Shares of NUVB stock opened at $3.82 on Tuesday. Nuvation Bio has a 12-month low of $3.71 and a 12-month high of $9.75. The firm has a market capitalization of $1.35 billion, a price-to-earnings ratio of -9.56 and a beta of 1.73. The company has a quick ratio of 7.30, a current ratio of 7.45 and a debt-to-equity ratio of 1.23. The firm has a fifty day moving average of $4.91 and a 200-day moving average of $5.30.

Nuvation Bio (NYSE:NUVB – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.12) EPS for the quarter, meeting analysts’ consensus estimates of ($0.12). The business had revenue of $44.95 million during the quarter, compared to analysts’ expectations of $34.39 million. Nuvation Bio had a negative net margin of 67.38% and a negative return on equity of 45.69%. On average, equities research analysts forecast that Nuvation Bio will post -0.37 earnings per share for the current year.

Institutional Investors Weigh In On Nuvation Bio

Several large investors have recently made changes to their positions in NUVB. Tema ETFs LLC increased its holdings in Nuvation Bio by 0.7% during the 2nd quarter. Tema ETFs LLC now owns 395,313 shares of the company’s stock worth $2,245,000 after purchasing an additional 2,559 shares in the last quarter. Tidal Investments LLC raised its stake in shares of Nuvation Bio by 0.7% in the 2nd quarter. Tidal Investments LLC now owns 395,313 shares of the company’s stock valued at $2,245,000 after purchasing an additional 2,559 shares during the period. Arizona State Retirement System lifted its holdings in shares of Nuvation Bio by 9.9% in the second quarter. Arizona State Retirement System now owns 66,946 shares of the company’s stock valued at $380,000 after purchasing an additional 6,015 shares in the last quarter. Sterling Capital Management LLC lifted its holdings in shares of Nuvation Bio by 847.9% in the third quarter. Sterling Capital Management LLC now owns 8,389 shares of the company’s stock valued at $47,000 after purchasing an additional 7,504 shares in the last quarter. Finally, KBC Group NV bought a new stake in shares of Nuvation Bio in the first quarter valued at about $37,000. Institutional investors own 61.67% of the company’s stock.

Nuvation Bio Company Profile

(Get Free Report)

Nuvation Bio is a biopharmaceutical company focused on developing and commercializing treatments for cancer. Founded in 2018 by physician and biotechnology executive David Hung, the company is headquartered in New York and is led by Hung as founder and chief executive officer. Its commercial product, Ibtrozi (taletrectinib), is an oral targeted therapy approved in the United States for adults with ROS1-positive non-small cell lung cancer. Nuvation Bio also develops investigational oncology medicines, including therapies targeting specific genetic changes and other features of cancer.

Recommended Stories

Analyst Recommendations for Nuvation Bio (NYSE:NUVB)

Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter.